Alternative mechanisms of telomere lengthening: Permissive mutations, DNA repair proteins and tumorigenic progression

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 743-744, Issue , 2013, Pages 142-150

  Gocha, April Renee Sandy ^a   Harris, Julia ^a   Groden, Joanna ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Alternative lengthening of telomeres; BLM; DNA repair; Immortalization; Telomerase; Telomere; Telomere maintenance; Tumor; WRN

Indexed keywords

ATRX PROTEIN; DAXX PROTEIN; H3F3A PROTEIN; MRE11 PROTEIN; NIBRIN; PROTEIN P53; RAD50 PROTEIN; TELOMERASE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE LENGTHENING OF TELOMERE; ATRX GENE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL IMMORTALIZATION; CELL PROLIFERATION; DAXX GENE; DNA REPAIR; ENZYME REGULATION; GENE MUTATION; GENOMIC INSTABILITY; H3F3A GENE; HUMAN; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TELOMERE HOMEOSTASIS; TUMOR GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DNA REPAIR; HUMANS; MUTATION; NEOPLASMS; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS;

MAMMALIA;

EID: 84877921184     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2012.11.006     Document Type: Review

References (86)

1. n, present at the telomeres of human chromosomes. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:6622-6626.
2. Griffith J.D., Comeau L., Rosenfield S., Stansel R.M., Bianchi A., Moss H., de Lange T. Mammalian telomeres end in a large duplex loop. Cell 1999, 97:503-514.
3. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005, 19:2100-2110.
4. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
5. Hastie N.D., Dempster M., Dunlop M.G., Thompson A.M., Green D.K., Allshire R.C. Telomere reduction in human colorectal carcinoma and with aging. Nature 1990, 346:866-868.
6. Lindsey J., McGill N.I., Lindsey L.A., Green D.K., Cooke H.J. In vivo loss of telomeric repeats with age in humans. Mutat. Res. 1991, 256:45-48.
7. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
8. Wright W.E., Piatyszek M.A., Rainey W.E., Byrd W., Shay J.W. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 1996, 18:173-179.
9. Stewart S.A., Hahn W.C., O'Connor B.F., Banner E.N., Lundberg A.S., Modha P., Mizuno H., Brooks M.W., Fleming M., Zimonjic D.B., Popescu N.C., Weinberg R.A. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12606-12611.
10. Bryan T.M., Englezou A., Gupta J., Bacchetti S., Reddel R.R. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995, 14:4240-4248.
11. Londono-Vallejo J.A., Der-Sarkissian H., Cazes L., Bacchetti S., Reddel R.R. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res. 2004, 64:2324-2327.
12. Dunham M.A., Neumann A.A., Fasching C.L., Reddel R.R. Telomere maintenance by recombination in human cells. Nat. Genet. 2000, 26:447-450.
13. Muntoni A., Neumann A.A., Hills M., Reddel R.R. Telomere elongation involves intra-molecular DNA replication in cells utilizing alternative lengthening of telomeres. Hum. Mol. Genet. 2009, 18:1017-1027.
14. Cesare A.J., Griffith J.D. Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol. Cell. Biol. 2004, 24:9948-9957.
15. Bryan T.M., Englezou A., Dalla-Pozza L., Dunham M.A., Reddel R.R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 1997, 3:1271-1274.
16. 2/M phase of the cell cycle. J. Cell Sci. 2000, 113:4577-4585.
17. Murnane J.P., Sabatier L., Marder B.A., Morgan W.F. Telomere dynamics in an immortal human cell line. EMBO J. 1994, 13:4953-4962.
18. Perrem K., Colgin L.M., Neumann A.A., Yeager T.R., Reddel R.R. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol. Cell. Biol. 2001, 21:3862-3875.
19. Yeager T.R., Neumann A.A., Englezou A., Huschtscha L.I., Noble J.R., Reddel R.R. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 1999, 59:4175-4179.
20. Hu J., Hwang S.S., Liesa M., Gan B., Sahin E., Jaskelioff M., Ding Z., Ying H., Boutin A.T., Zhang H., Johnson S., Ivanova E., Kost-Alimova M., Protopopov A., Wang Y.A., Shirihai O.S., Chin L., DePinho R.A. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 2012, 148:651-663.
21. Henson J.D., Reddel R.R., Assaying investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett. 2010, 584:3800-3811.
22. Heaphy C.M., Subhawong A.P., Hong S.M., Goggins M.G., Montgomery E.A., Gabrielson E., Netto G.J., Epstein J.I., Lotan T.L., Westra W.H., Shih I.M., Iacobuzio-Donahue C.A., Maitra A., Li Q.K., Eberhart C.G., Taube J.M., Rakheja D., Kurman R.J., Wu T.C., Roden R.B., Argani P., De Marzo A.M., Terracciano L., Torbenson M., Meeker A.K. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am. J. Pathol. 2011, 179:1608-1615.
23. Zimmermann S., Voss M., Kaiser S., Kapp U., Waller C.F., Martens U.M. Lack of telomerase activity in human mesenchymal stem cells. Leukemia 2003, 17:1146-1149.
24. Serakinci N., Hoare S.F., Kassem M., Atkinson S.P., Keith W.N. Telomerase promoter regprogramming and interaction with general transcription factors in the human mesenchymal stem cell. Regen. Med. 2006, 1:125-131.
25. Sun B., Huang Q., Liu S., Chen M., Hawks C.L., Wang L., Zhang C., Hornsby P.J. Progressive loss of malignant behavior in telomerase-negative tumorigenic adrenocortical cell and restoration of tumorigenicity by human telomerase reverse transcriptase. Cancer Res. 2004, 64:6144-6151.
26. Farazi P.A., Glickman J., Jiang S., Yu A., Rudolph K.L., DePinho R.A. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res. 2003, 63:5021-5027.
27. Chin L., Artandi S.E., Shen Q., Tam A., Lee S.-L., Gottlieb G.J., Greider C.W., DePinho R.A. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999, 97:527-538.
28. Artandi S.E., Chang S., Lee S.-L., Alson S., Gottlieb G.J., Chin L., DePinho R.A. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000, 406:641-645.
29. O'Hagan R.C., Chang S., Maser R.S., Mohan R., Artandi S.E., Chin L., DePinho R.A. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2002, 2:149-155.
30. Suram A., Kaplunov J., Patel P.L., Ruan H., Cerutti A., Boccardi V., Fumagalli M., Di Micco R., Mirani N., Gurung R.L., Hande M.P., d'Adda di Fagagna F., Herbig U. Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J. 2012, 31:2839-2851.
31. Kyo S., Takakura M., Fujiwara T., Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008, 99:1528-1538.
32. Zhu J., Zhao Y., Wang S. Chromatin and epigenetic regulation of the telomerase reverse transcriptase gene. Protein Cell 2010, 1:22-32.
33. Sengupta S., Harris C.C. p53: traffic cop at the crossroads of DNA repair and recombination. Nat. Rev. Mol. Cell Biol. 2005, 6:44-55.
34. Bertrand P., Rouillard D., Boulet A., Levalois C., Soussi T., Lopez B.S. Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein. Oncogene 1997, 14:1117-1122.
35. Razak Z.R., Varkonyi R.J., Kulp-McEliece M., Caslini C., Testa J.R., Murphy M.E., Broccoli D. p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance. Mol. Cell. Biol. 2004, 24:5967-5976.
36. Akyüz N., Boehden G.S., Süsse S., Rimek A., Preuss U., Scheidtmann K.H., Wiesmüller L. DNA substrate dependence of p53-mediated regulation of double strand break repair. Mol. Cell. Biol. 2002, 22:6306-6317.
37. Farazi P.A., Glickman J., Horner J., DePinho R.A. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res. 2006, 66:4766-4773.
38. Perera S.A., Maser R.S., Xia H., McNamara K., Protopopov A., Chen L., Hezel A.F., Kim C.F., Bronson R.T., Castrillon D.H., Chin L., Bardeesy N., DePinho R.A., Wong K.-K. Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. Carcinogenesis 2008, 29:747-753.
39. Hakin-Smith V., Jellinek D.A., Levy D., Carroll T., Teo M., Timperley W.R., McKay M.J., Reddel R.R., Royds J.A. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003, 361:836-838.
40. Chen Y., Hakin-Smith V., Teo M., Xinarianos G.E., Jellinek D.A., Carroll T., McDowell D., MacFarlane M.R., Boet R., Baguley B.C., Braithwaite A.W., Reddel R.R., Royds J.A. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res. 2006, 66:6473-6576.
41. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical utility, Cold Spring Harb. Perspect. Biol. 2010, 2:a001008. 10.1101/cshperspect.a001008.
42. Tang J., Wu S., Liu H., Stratt R., Barak O.G., Shiekhattr R., Picketts D.J., Yang X. A novel transcription regulatory complex containing death domain-associated protein and the ATR-X syndrome protein. J. Biol. Chem. 2004, 279:20369-20377.
43. Law M.J., Lower K.M., Voon H.P.J., Hughes J.R., Garrick D., Viprakasit V., Mitson M., de Gobbi M., Marra M., Morris A., Abbott A., Wilder S.P., Taylor S., Santos G.M., Cross J., Ayyub H., Jones S., Ragoussis J., Rhodes D., Dunham I., Higgs D.R., Gibbons R.J. ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. Cell 2010, 143:367-378.
44. Lewis P., Elsaesser S., Noh K., Stadler S., Allis C.D. DAXX is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14075-14080.
45. Goldberg A.D., Banaszynski L.A., Noh K., Lewis P.W., Elsaesser S.J., Stadler S., Dewell S., Law M., Guo X., Li X., Wen D., Chapgier A., DeKelver R.C., Miller J.C., Lee Y., Boydston E.A., Holmes M.C., Gregory P.D., Greally J.M., Rafii S., Yang C., Scambler P.J., Garrick D., Gibbons R.J., Higgs D.R., Cristea I.M., Urnov F.D., Zheng D., Allis C.D. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010, 140:678-691.
46. Ahmad K., Henikoff S. The histone variant H3.3 marks active chromatin by replication-independent nucleosome assembly. Mol. Cell 2002, 9:1191-2000.
47. Wong L., Ren H., Williams E., McGhie J., Ahn S., Sim M., Tam A., Earle E., Anderson M., Mann J., Choo K.H.A. Histone H3.3 incorporation provides a unique and functionally essential telomeric chromatin in embryonic stem cells. Genome Res. 2009, 19:404-414.
48. Heaphy C.M., de Wilde R.F., Jiao Y., Klein A.P., Edil B.H., Shi C., Bettegowda C., Rodriguez F.J., Eberhart C.G., Hebbar S., Offerhaus G.J., McLendon R., Rasheed B.A., He Y., Yan H., Bigner D.D., Oba-Shinjo S.M., Marie S.K.N., Riggins G.J., Kinzler K.W., Vogelstein B., Hruban R.H., Maitra A., Papadopoulos N., Meeker A.K. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333:6041.
49. Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1). Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24:355-370.
50. de Wilde R.F., Heaphy C.M., Maitra A., Meeker A.K., Edil B.H., Wolfgan C.L., Ellison T.A., Schulick R.D., Molenaar I.Q., Valk G.D., Vriens M.R., Borel Rinkes I.H.M., Offerhaus G.J.A., Hruban R.H., Matsukuma K.E. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod. Pathol. 2012, 25:1033-1039.
51. Lovejoy C.A., Li W., Reisenweber S., Thongthip S., Bruno J., de Lange T., De S., Petrini J.H., Sung P.A., Jasin M., Rosenbluh J., Zwang Y., Weir B.A., Hatton C., Ivanova E., Macconaill L., Hanna M., Hahn W.C., Lue N.F., Reddel R.R., Jiao Y., Kinzler K., Vogelstein B., Papadopoulos N., Meeker A.K. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 2012, 8:e1002772. 10.1371/journal.pgen.1002772.
52. Schwartzentruber J., Korshunov A., Liu X.-Y., Jones D.T.W., Pfaff E., Jacob K., Sturm D., Fontebasso A.M., Quang D., Tönjes M., Hovestadt V., Albrecht S., Kool M., Nantel A., Konermann C., Lindroth A., Jäger N., Rausch T., Ryzhova M., Korbel J.O., Hielscher T., Hauser P., Garami M., Klekner A., Bognar L., Ebinger M., Schuhmann M.U., Scheurlen W., Pekrun A., Frühwald M.C., Roggendorf W., Kramm C., Dürken M., Atkinson J., Lepage P., Montpetit A., Zakrzewska M., Zakrzewski K., Liberski P.P., Dong Z., Siegel P., Kulozik A.E., Zapatka M., Guha A., Malkin D., Felsberg J., Reifenberger G., von Deimling A., Ichimura K., Collins V.P., Witt H., Milde T., Witt O., Zhang C., Castelo-Branco P., Lichter P., Faury D., Tabori U., Plass C., Majewski J., Pfister S.M., Jabado N. Driver mutations in histone H3.3 and chromatin remodeling genes in pediatric glioblastoma. Nature 2012, 484:130.
53. Lafferty-Whyte K., Cairney C.J., Will M.B., Serakinci N., Daidone M.-G., Zaffaroni N., Bilsland A., Keith W.N. A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene 2009, 28:3765-3774.
54. Lafferty-Whyte K., Bilsland A., Hoare S.F., Burns S., Zaffaroni N., Cairney C.J., Keith W.N. TCEAL7 inhibition of c-MYC activity in alternative lengthening of telomeres regulates hTERT expression. Neoplasia 2010, 12:405-414.
55. Wu K.J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., Dalla-Favera R. Direct activation of TERT transcription by c-MYC. Nat. Genet. 1999, 21:220-224.
56. A.R.S. Gocha, G. Nuovo, O.H. Iwenofu, J. Groden, Human sarcomas are mosaic for telomerase-dependent and -independent telomere maintenance mechanisms: implications for telomere-based therapies, Am. J. Pathol., in press.
57. Jiang W.Q., Zhong Z.H., Henson J.D., Neumann A.A., Chang A.C., Reddel R.R. Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol. Cell. Biol. 2005, 25:2708-2721.
58. Zhong Z.H., Jiang W.Q., Cesare A.J., Neumann A.A., Wadhwa R., Reddel R.R. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J. Biol. Chem. 2007, 282:29314-29322.
59. Compton S.A., Choi J.H., Cesare A.J., Ozgür S., Griffith J.D. Xrcc3 and Nbs1 are required for the production of extrachromosomal telomeric circles in human alternative lengthening of telomere cells. Cancer Res. 2007, 67:1513-1519.
60. Potts P.R., Yu H. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat. Struct. Mol. Biol. 2007, 14:581-590.
61. Bhattacharyya S., Keirsey J., Russell B., Kavecansky J., Lillard-Wetherell K., Tahmaseb K., Turchi J.J., Groden J. Telomerase-associated protein 1, HSP90, and topoisomerase IIα associate directly with the BLM helicase in immortalized cells using ALT and modulate its helicase activity using telomeric DNA substrates. J. Biol. Chem. 2009, 284:14966-14977.
62. Temime-Smaali N., Guittat L., Wenner T., Bayart E., Douarre C., Gomez D., Giraud-Panis M.J., Londono-Vallejo A., Gilson E., Amor-Guéret M., Riou J.F. Topoisomerase IIIα is required for normal proliferation and telomere stability in alternative lengthening of telomeres. EMBO J. 2008, 27:1513-1524.
63. A.R.S. Gocha, S. Acharya, J. Groden, A variable requirement for the WRN helicase in human cell lines using ALT suggests multiple mechanisms of telomere maintenance in the absence of telomerase, in preparation.
64. Fasching C.L., Bower K., Reddel R.R. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res. 2005, 65:2722-2729.
65. Zeng S., Xiang T., Pandita T.K., Gonzalez-Suarez I., Gonzalo S., Harris C.C., Yang Q. Telomere recombination requires the MUS81 endonuclease. Nat. Cell Biol. 2009, 11:616-623.
66. Grudic A., Jul-Larsen A., Haring S.J., Wold M.S., Lønning P.E., Bjerkvig R., Bøe S.O. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Res. 2007, 35:7267-7278.
67. Li B., Reddy S., Comai L. Depletion of Ku70/80 reduces the levels of extrachromosomal telomeric circles and inhibits proliferation of ALT cells. Aging (Milano) 2011, 3:395-406.
68. Saharia A., Stewart S.A. FEN1 contributes to telomere stability in ALT-positive tumor cells. Oncogene 2009, 28:1162-1167.
69. Fan Q., Zhang F., Barrett B., Ren K., Andreassen P.R. A role for monoubiquitinated FANCD2 at telomeres in ALT cells. Nucleic Acids Res. 2009, 37:1740-1754.
70. Tarsounas M., Muñoz P., Claas A., Smiraldo P.G., Pittman D.L., Blasco M.A., West S.C. Telomere maintenance requires the RAD51D recombination/repair protein. Cell 2004, 117:337-347.
71. Jiang W.Q., Zhong Z.H., Henson J.D., Reddel R.R. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene 2007, 26:4635-4647.
72. Stagno D'Alcontres M., Mendez-Bermudez A., Foxon J.L., Royle N.J., Salomoni P. Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA. J. Cell Biol. 2007, 179:855-867.
73. Nabetani A., Ishikawa F. Alternative lengthening of telomeres pathway: recombination-mediated telomere maintenance mechanism in human cells. J. Biochem. 2011, 149:5-14.
74. Bednarek A., Budunova I., Slaga T.J., Aldaz C.M. Increased telomerase activity in mouse skin premalignant progression. Cancer Res. 1995, 55:4566-4569.
75. Blasco M.A., Rizen M., Greider C.W., Hanahan D. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat. Genet. 1996, 12:200-204.
76. Δ2/3 cancer-prone mouse. Cell 1999, 97:515-525.
77. Chang S., Khoo C.M., Naylor M.L., Maser R.S., DePinho R.A. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev. 2003, 17:88-100.
78. Ding Z., Wu C.-J., Jaskelioff M., Ivanova E., Kost-Alimova M., Protopopov A., Chu G.C., Wang G., Lu X., Labrot E.S., Hu J., Wang W., Xiao Y., Zhang H., Zhang J., Zhang J., Gan B., Perry S.R., Jiang S., Li L., Homer J.W., Wang Y.A., Chin L., DePinho R.A. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 2012, 148:1-12.
79. Sotillo-Piñeiro E., Sierrasesúmaga L., Patiño-García A. Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients. Pediatr. Res. 2004, 55:231-235.
80. Henson J.D., Hannay J.A., McCarthy S.W., Royds J.A., Yeager T.R., Robinson R.A., Wharton S., Jellinek D.A., Arbuckle S.M., Yoo J., Robinson B.G., Learoyd D.L., Stalley P.D., Bonar S.F., Yu D., Pollock R.E., Reddel R.R. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin. Cancer Res. 2005, 11:217-225.
81. Costa A., Daidone M.G., Daprai L., Villa R., Cantù S., Pilotti S., Mariani L., Gronchi A., Henson J.D., Reddel R.R., Zaffaroni N. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res. 2006, 66:8918-8924.
82. Hiyama E., Hiyama K., Yokoyama T., Shay J.W. Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia 2001, 3:17-26.
83. Villa R., Daidone M.G., Motta R., Venturini L., De Marco C., Vannelli A., Kusamura S., Baratti D., Deraco M., Costa A., Reddel R.R., Zaffaroni N. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin. Cancer Res. 2008, 14:4134-4140.
84. Sanders R.P., Drissi R., Billups C.A., Daw N.C., Valentine M.B., Dome J.S. Telomerase expression predicts unfavorable outcome in osteosarcoma. J. Clin. Oncol. 2004, 22:3790-3797.
85. Matsuo T., Shay J.W., Wright W.E., Hiyama E., Shimose S., Kubo T., Sugita T., Yasunaga Y., Ochi M. Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas. J. Bone Joint Surg. Am. 2009, 91:928-937.
86. Onitake Y., Hiyama E., Kamei N., Yamaoka H., Sueda T., Hiyama K. Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres. J. Pediatr. Surg. 2009, 44:2258-2266.